WashingtonRegenxbio will file for Duchenne therapy approval.
Last month Regenxbio said regulators wanted another trial; it reversed course after 2 Food and Drug Administration officials who rejected related therapies resigned.
No federal drug reviewer has publicly changed stance on the therapy; the filing proceeds without new trial data.
Sources: STAT